Тестостерон и сердечно-сосудистые риски: мифы и новая правда о кардиологической безопасности андрогенозаместительной терапии у мужчин
https://doi.org/10.17650/2070-9781-2014-3-42-51
Аннотация
Об авторах
С. Ю. Калинченко
ФГБОУ ВПО «Российский университет дружбы народов»
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Игорь Адамович Тюзиков
ООО Клиника «Гармония»
Россия
Ярославль
Россия
Ярославль
Л. О. Ворслов
ФГБОУ ВПО «Российский университет дружбы народов»
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Ю. А. Тишова
ФГБОУ ВПО «Российский университет дружбы народов»
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Россия
Кафедра эндокринологии факультета повышения квалификации медицинских работников, Москва
Список литературы
1. Карчикян С.И. Об эссенциальной гипертонии и ее лечении на Кисловодском курорте. Клин мед 1930;8(2):49–58.
2. Глухенький Т.Т. Лечение гипертонии эндокринными препаратами. Врач дело 1946; 11–12:919–22.
3. Walker T.С. Use of testosterone propionate and estrogenic substances in treatment of essential hypertension, angina pectoris and peripheral vascular diseases. J Clin Endocrinol 1942;2:560–8.
4. Jaffe M.D. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977;39(11):1217–22.
5. English K.M., Steeds R.P., Jones T.H. et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102(16):1906–11.
6. Zhang L., Wu S., Ruan Y. et al. Testosterone suppresses oxidative stress via androgen receptorindependent pathway in murine cardiomyocytes. Mol Med Rep 2011;4(6):1183–8.
7. Lee A.M., Chu L.W., Chong C.S. et al. Relationship between symptoms of androgen deficiency and psychological factors and quality of life among Chinese men. Int J Androl 2010;33(5):755–63.
8. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87(2):682–5.
9. Stuehr D.J., Kwon N.S., Nathan C.F. et al. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991;266(10): 6259–63.
10. Zhao C., Moon du G., Park J.K. Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. Can Urol Assoc J 2013;7(3–4):221–5.
11. Tylińska M., Broncel M. The relationship between testosterone deficiency and metabolic syndrome in obese men. Pol Merkur Lekarski 2013;34(199):24–8.
12. Rubinow K.B., Vaisar T., Tang C. et al. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res 2012;53(7):1376–83.
13. Monroe A.K., Dobs A.S. The effect of androgens on lipids. Curr Opin Endocrinol Diabetes Obes 2013;20(2):132–9.
14. Wu F.C., von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24(2):183–217.
15. Miner M., Barkin J., Rosenberg M.T. Testosterone deficiency: myth, facts, and controversy. Can J Urol 2014;21(3):39–54.
16. Maganty A., Osterberg E.C., Ramasamy R. Hypogonadism and testosterone therapy: associations with cardiovascular risk. Am J Mens Health 2014;pii: 1557988314540933. [Epub ahead of print].
17. Kelly D.M., Jones T.H. Testosterone and cardiovascular risk in men. Front Horm Res 2014;43:1–20.
18. Traish A.M. Adverse health effects of testosterone deficiency (TD) in men. Steroids 2014;88С:106–16.
19. Zitzmann M., Mattern A., Hanisch J. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10(2):579–88.
20. Toma M., McAlister F.A., Coglianese E.E. et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012; 5(3):315–21.
21. Corona G., Rastrelli G., Monami M. et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a metaanalytic study. Eur J Endocrinol 2011;165(5): 687–701.
22. Araujo A.B., Dixon J.M., Suarez E.A. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96(10):3007–19.
23. Ruige J.B., Mahmoud A.M., De Bacquer D., Kaufman J.M. Endogenous testosterone and cardiovascular disease in healthy men: a metaanalysis. Heart 2011;97(11):870–5.
24. Corona G., Monami M., Rastrelli G. et al. Testosterone and metabolic syndrome: a metaanalysis study. J Sex Med 2011;8(1):272–83.
25. Tan W.S., Ng C.J., Khoo E.M. et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male 2011;14(4):231–6.
26. Bhasin S., Cunningham G.R., Hayes F.J. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59.
27. Dandona P., Rosenberg M.T. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract 2010;64:682–96.
28. Dohle G.R., Arver S., Bettocchi C. et al. Guidelines on Male Hypogonadism. EAU, 2014.
29. Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159(5):507–14.
30. Hak A.E., Witteman J.C., de Jong F.H. et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002;87(8):3632–9.
31. Marin P., Holmäng S., Gusrafsson C. et al. Androgen treatment of abdominally obese men. Obes Res 1993;1(4):245–51.
32. Kalinchenko S.Y., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal nien with the metabolic syndrome: the double-blinded placebo-controlled Moscow srudy. Clin Endocrinol (Oxf) 2010;73(5):602–12.
33. Jones T.H., Arver S., Behre H.M. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37.
34. Haring R., Baumeister S.E., Volzke H. et al. Prospective inverse associations of sex hormone concentrations in men with biomarkers of inflammation and oxidative stress. J Androl 2012;33:944–50.
35. Baillargeon J., Urban R.J., Kuo Y.F. et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014;48(9):1138–44.
36. Scovell J., Ramasamy R., Kovac J.R. A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men. Can Urol Assoc J 2014; 8(5–6):356–7.
37. Martínez-Jabaloyas J.M.; DE-SDT study group. Testosterone deficiency in patients with erectile dysfunction: when should a higher cardiovascular risk be considered? J Sex Med 2014;11(8):2083–91.
38. Hackett G., Kirby M., Sinclair A.J. Testosterone deficiency, cardiac health, and older men. Int J Endocrinol 2014;2014: 143763.
39. Moncada I. Testosterone and men’s quality of life. Aging Male 2006;9(4):189–93.
40. Snyder P.J., Peachey H., Berlin J.A. et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670–7.
41. Wang C., Alexander G., Berman N. et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3578–83.
42. Wang C., Cunningham G., Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89(5):2085–98.
43. Yassin A.A., Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497–501.
44. Hackett G., Cole N., Bhartia M. et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST Study. J Sex Med 2014;11(3):840–56.
45. He J., Bhasin S., Binder E.F. et al. Cardiometabolic risks during anabolic hormone supplementation in older men. Obesity (Silver Spring) 2013;21(5):968–75.
46. Corona G., Monami M., Rastrelli G. et al. Type 2 diabetes mellitus and testosterone: A meta-analysis study. Int J Androl 2011; 34(6 Pt 1):528–40.
47. Cauley J.A., Gutai J.P., Kuller L.H., Dai W.S. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1981;60(10):771–7.
48. Basaria S., Coviello A.D., Travison T.G. et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109–22.
49. Ho C.C., Tong S.F., Low W.Y. et al. A randomized, double-blind, placebocontrolled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012;110(2): 260–5.
50. Khaw K.T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPICNorfolk) Prospective Population Srudy. Circulacion 2007;116(23):2694–701.
51. Menke A., Guallar E., Robrmann S. et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171(5):583–92.
52. Schooling C.M. Testosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2014;21(3):202–8.
53. Merza Z., Blumsohn A., Mah P.M. et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turn over in men with borderline hypogonadism. Int J Androl 2006;29(3):81–91.
54. Svartberg J., Agledahl I., Figenschau Y. et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20(4):378–87.
55. Aversa A., Bruzziches R., Francomano D. et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with lateonset hypogonadism and metabolic syndrome: results from a 24-month, randomized, doubleblind, placebo-controlled study. J Sex Med 2010;7(10):3495–503.
56. Svartberg J., Aasebø U., Hjalmarsen A. et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004;98(9):906–13.
57. Hoyos C.M., Yee B.J., Phillips C.L. et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012;167(4):531–41.
58. Tan R.S., Cook K.R., Reilly W.G. High Estrogen in men after injectable testosterone therapy: the low Т experience. Am J Mens Health 2014. pii: 1557988314539000.
59. www.fda.gov.
60. Vigen R., O’Donnell O., Barоn A. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310(17):1829–36.
61. Finkle W.D., Greenland S., Ridgeway G.K. et al. Increased risks of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014; 9(1):e85805.
62. Xu L., Freeman G., Cowling B. et al. Testosterone therapy and cardiovascular events among men: a systematic review and metaanalysis of placebo-controlled trials. BMC Med 2013;11:108.
63. Morgentaler A., Traish A., Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA 2014;311(9):961–2.
64. Morales A. Testosterone deficiency syndrome and cardiovascular health: Looking carefully at the evidence. Can Urol Assoc J 2014;8(1–2):34–5.
65. Morgentaler A. Testosterone, cardiovascular risk and hormonophobia. J Sex Med 2014;11(6):1362–6.
66. Page S.T. Testosterone, cardiovascular disease, and mortality in men: living in the dark. Lancet Diabetes Endocrinol 2014; 2(8):609–11.
67. Seftel A.D., Morgentaler A. Does testosterone increase the risk of a cardiovascular event? J Urol 2014. pii: S0022-5347(14)03349-7.
68. Morgentaler A., Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 2014;17(2):63–5.
69. Calof O.M., Singh A.B., Lee M.L. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebocontrolled trials. J Gerontol Biol Med Sci 2005;60(11):1451–7.
70. Haddad R.M., Kennedy C.C., Caples S.M. et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82(1):29–39.
71. Gruenewald D.A., Matsumoto A.M. Testosterone supplementation therapy for older men: potential benefits and risks. Am Geriatr Soc 2003;51(1):101–5.
72. Lunenfeld B., Mskhalaya G., Kalinchenko S., Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;16(4):143–58.
73. Fernández-Balsells M.M., Murad M.H., Lane M. et al. Сlinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(6):2560–75.
74. Dobs A.S., Meikle A.W., Arver S. et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84(10):3469–78.
75. Jones T.H., Saad F. The effects of testosterone on risk factors for, and the mediators of the atherosclerotic process. Atherosclerosis 2009;207(2):318–27.
76. Chrysant S.G. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013;15(5):475–83.
77. Yeap B.B., Alfonso H., Chubb S.A. et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab 2014;99(1): 9–18.
78. Ramasamy R., Kovac J.R., Scovell J.M. et al. Words of wisdom. Re: In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Eur Urol 2014; 65(4):844–5.
79. Ajayi A.A., Mathur R., Halushka P.V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995; 91(11):2742–7.
80. Kunnas T., Solakivi T., Huuskonen K. et al. Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev Med 2009;49(1):45–7.
81. Sorlie P.D., Garcia-Palmieri M.R., Costas R. Jr. et al. Hematocrit and risk of coronary heart disease: The Puerto Rico Health Program. Am Heart J 1981;101(4):456–61.
82. Залманов А.С. Тайная мудрость человеческого организма. М., 1963.
83. Радзинский В.Е. Акушерская агрессия. М., 2011.
Рецензия
Для цитирования:
Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О., Тишова Ю.А. Тестостерон и сердечно-сосудистые риски: мифы и новая правда о кардиологической безопасности андрогенозаместительной терапии у мужчин. Андрология и генитальная хирургия. 2014;15(3):42-51. https://doi.org/10.17650/2070-9781-2014-3-42-51
For citation:
Kalinchenko S.Yu., Tyuzikov I.A., Vorslov L.O., Tishova Yu.A. Testosterone and cardiovascular risk: myths and new truth about cardiological safety of androgen replacement therapy in men. Andrology and Genital Surgery. 2014;15(3):42-51. (In Russ.) https://doi.org/10.17650/2070-9781-2014-3-42-51
Просмотров: 1159
Послать статью по эл. почте 